The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Andreas Wicki Biography and Net Worth

Director of Harmony Biosciences

Successful healthcare entrepreneur and investor with over 25 years of experience in the pharmaceutical and biotechnology industries. MSc and PhD in chemistry and biochemistry from the University of Berne, Switzerland. Previously co-owner and CEO of ANAWA Holding AG and Clinserve AG, two Contract Research Organisations specialising in analytical services. Board member of Harmony Biosciences, Buchler, and Pacira Pharmaceuticals.

What is Andreas Wicki's net worth?: The estimated net worth of Andreas Wicki is at least $70.43 million as of December 14th, 2022. Dr. Wicki owns 2,147,943 shares of Harmony Biosciences stock worth more than $70,431,051 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Wicki may own. Learn More about Andreas Wicki's net worth.
How do I contact Andreas Wicki?: The corporate mailing address for Dr. Wicki and other Harmony Biosciences executives is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. Harmony Biosciences can also be reached via phone at 484-539-9800 and via email at [email protected]. Learn More on Andreas Wicki's contact information.
Has Andreas Wicki been buying or selling shares of Harmony Biosciences?: Andreas Wicki has not been actively trading shares of Harmony Biosciences in the last ninety days. Most recently, Andreas Wicki sold 130 shares of the business's stock in a transaction on Wednesday, December 14th. The shares were sold at an average price of $60.00, for a transaction totalling $7,800.00. Following the completion of the sale, the director now directly owns 2,147,943 shares of the company's stock, valued at $128,876,580. Learn More on Andreas Wicki's trading history.
Who are Harmony Biosciences' active insiders?: Harmony Biosciences' insider roster includes Jeffrey Dayno (Insider), Jeffrey Dierks (Insider), John Jacobs (CEO), and Andreas Wicki (Director). Learn More on Harmony Biosciences' active insiders.
Are insiders buying or selling shares of Harmony Biosciences?: In the last year, insiders at the sold shares 4 times. They sold a total of 33,869 shares worth more than $1,267,489.12. The most recent insider tranaction occured on October, 29th when insider Jeffrey Dierks sold 21,496 shares worth more than $869,943.12. Insiders at Harmony Biosciences own 30.8% of the company. Learn More about insider trades at Harmony Biosciences.
Information on this page was last updated on 10/29/2024.

Andreas Wicki Insider Trading History at Harmony Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/14/2022	Sell	130	$60.00	$7,800.00	2,147,943
12/12/2022	Sell	22,391	$60.36	$1,351,520.76	2,154,393
12/5/2022	Sell	77,853	$61.23	$4,766,939.19	2,176,784
11/10/2022	Sell	95,242	$58.80	$5,600,229.60	2,305,915
11/8/2022	Sell	18,865	$60.01	$1,132,088.65	2,416,458
11/4/2022	Sell	157,950	$58.81	$9,289,039.50	2,435,323
11/2/2022	Sell	164,676	$58.81	$9,684,595.56	2,847,414
8/10/2022	Sell	71,447	$52.61	$3,758,826.67	3,012,090
8/4/2022	Sell	12,640	$52.67	$665,748.80	3,620,124
3/11/2022	Sell	70,370	$44.14	$3,106,131.80
3/9/2022	Sell	140,000	$45.49	$6,368,600.00
3/3/2022	Sell	175,000	$41.01	$7,176,750.00
3/1/2022	Sell	92,501	$40.24	$3,722,240.24
12/10/2021	Sell	2,585	$40.08	$103,606.80
12/8/2021	Sell	24,683	$40.09	$989,541.47
11/17/2021	Sell	1,417	$41.25	$58,451.25
11/15/2021	Sell	35,600	$42.08	$1,498,048.00

Andreas Wicki Buying and Selling Activity at Harmony Biosciences

Harmony Biosciences Company Overview

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Today's Range

Now: $32.79

$32.40

$33.66

50 Day Range

MA: $35.80

$32.13

$41.49

2 Week Range

Now: $32.79

$27.14

$41.61

Volume

311,020 shs

Average Volume

1,242,829 shs

Market Capitalization

$1.87 billion

P/E Ratio

15.54

Dividend Yield

N/A

Beta

0.77

Financial Prophecy

From Porter & Company | Ad